SCS Capital Management LLC Cuts Stock Position in Johnson & Johnson $JNJ

SCS Capital Management LLC lessened its stake in Johnson & Johnson (NYSE:JNJ) by 2.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 161,365 shares of the company’s stock after selling 4,300 shares during the period. SCS Capital Management LLC’s holdings in Johnson & Johnson were worth $33,394,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its stake in shares of Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after acquiring an additional 6,332 shares during the last quarter. United Bank grew its stake in shares of Johnson & Johnson by 110.7% during the first quarter. United Bank now owns 9,279 shares of the company’s stock worth $1,539,000 after acquiring an additional 4,876 shares during the last quarter. Sivia Capital Partners LLC grew its stake in shares of Johnson & Johnson by 13.4% during the second quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock worth $896,000 after acquiring an additional 692 shares during the last quarter. Wealth Group Ltd. grew its stake in shares of Johnson & Johnson by 12.8% during the second quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock worth $226,000 after acquiring an additional 168 shares during the last quarter. Finally, Schnieders Capital Management LLC. grew its stake in shares of Johnson & Johnson by 9.8% during the second quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company’s stock worth $11,255,000 after acquiring an additional 6,584 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on JNJ shares. Weiss Ratings lowered Johnson & Johnson from a “buy (b+)” rating to a “buy (b)” rating in a research note on Friday, April 24th. TD Cowen assumed coverage on Johnson & Johnson in a research report on Wednesday, April 8th. They issued a “buy” rating and a $250.00 target price on the stock. Raymond James Financial upped their target price on Johnson & Johnson from $237.00 to $258.00 and gave the company an “outperform” rating in a research report on Wednesday, April 15th. Johnson Rice upgraded Johnson & Johnson from a “hold” rating to an “outperform” rating in a research report on Wednesday, May 13th. Finally, Wall Street Zen lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Twenty equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $253.04.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: J&J reported strong Phase 3 results for Erleada (apalutamide) in prostate cancer. The PROTEUS study met both primary endpoints, showing a lower risk of metastasis or death and a much higher likelihood of little to no cancer remaining after surgery, which could expand the drug’s role and support future oncology sales. Article: J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study
• Positive Sentiment: RYBREVANT FASPRO showed durable responses in advanced head and neck cancer in the OrigAMI-4 study, including a 42% confirmed response rate and complete responses in more than one-third of responders. J&J also submitted the therapy to the FDA for approval in this setting, adding another potential growth driver if the label is expanded. Article: RYBREVANT FASPRO pivotal data show strong and durable responses in advanced head and neck cancer
• Positive Sentiment: Several pieces highlighted J&J as a strong dividend stock, reinforcing its appeal as a low-beta, income-oriented healthcare name for investors seeking stability. Article: Is Johnson & Johnson one of the best dividend paying stocks to buy right now?
• Neutral Sentiment: A market recap article noted that JNJ stock was down 2.4% and questioned whether it is time to sell, but it did not provide a new company-specific catalyst beyond the recent move. Article: Johnson & Johnson stock price down 2.4% – time to sell?

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $225.16 on Monday. Johnson & Johnson has a 52 week low of $149.04 and a 52 week high of $251.71. The firm has a market cap of $542.01 billion, a P/E ratio of 26.03, a P/E/G ratio of 2.21 and a beta of 0.26. The business’s 50 day moving average price is $233.02 and its 200 day moving average price is $225.07. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The company had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. During the same period in the previous year, the company posted $2.77 earnings per share. Johnson & Johnson’s revenue for the quarter was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, sell-side analysts expect that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be issued a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, May 26th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 dividend on an annualized basis and a yield of 2.4%. Johnson & Johnson’s dividend payout ratio is presently 61.97%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.